CN Mobile Logo

Search form



ASCO Annual Meeting

Cancer Network presents exclusive coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Check out some of our topic specific ASCO coverage:

Breast Cancer | Hematologic Malignancies | Lung Cancer | Multiple Myeloma | Ovarian Cancer | Prostate Cancer | Renal Cell Carcinoma | Street Team


The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.

In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed/refractory patients.

A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding tumor tissue in patients with metastatic breast, lung, and prostate cancer.

A new study found that patients with mCRPC had higher PSA response with enzalutamide vs abiraterone, but no difference in time to progression, and reported worse outcomes in those with quantifiable ctDNA.

The second-generation ALK-inhibitor alectinib should be the new standard of care for first-line treatment of ALK-positive non–small-cell lung cancer, according to a new study.

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

CAR T-cell therapy targeting B-cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.


Subscribe to ASCO on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.